Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-18T21:19:01.928Z Has data issue: false hasContentIssue false

Hallucinogenic drug induced states resemble acute endogenous psychoses: results of an empirical study

Published online by Cambridge University Press:  16 April 2020

E Gouzoulis-Mayfrank
Affiliation:
Department of Psychiatry and Psychotherapy, Medical Faculty of the University of Technology (RWTH), Pauwelsstrasse 30, D-52074Aachen
E Habermeyer
Affiliation:
Department of Psychiatry and Psychotherapy, Medical Faculty of the University of Technology (RWTH), Pauwelsstrasse 30, D-52074Aachen
L Hermle
Affiliation:
Psychiatric Hospital Christophsbad, Gtippingen, Germany
AM Steinmeyer
Affiliation:
Department of Psychiatry and Psychotherapy, Medical Faculty of the University of Technology (RWTH), Pauwelsstrasse 30, D-52074Aachen
HJ Kunert
Affiliation:
Department of Psychiatry and Psychotherapy, Medical Faculty of the University of Technology (RWTH), Pauwelsstrasse 30, D-52074Aachen
H Sass
Affiliation:
Department of Psychiatry and Psychotherapy, Medical Faculty of the University of Technology (RWTH), Pauwelsstrasse 30, D-52074Aachen
Get access

Summary

Clinical evidence suggests that hallucinogenic drug-induced altered states of consciousness (ASCs) and the incipient, acute stages of endogenous psychoses share many common phenomenological features. The aim of our study was to assess hallucinogen-like phenomena in endogenous psychotic patients using standardised methods. We examined 93 endogenous psychotic patients, 50 healthy controls and a small group of drug induced psychotic patients (n = 7) with two ASC self-assessment scales (questionnaire APZ = Abnormer Psychischer Zustand = Altered State of Consciousness [Dittrich et al, 1985]; and questionnaire OAV = Abbreviation of the three subscales: Oceanic Boundlessness/Angst = Dread of Ego Dissolution/Visionary Restructuralisation [Bodmer 1989]). Patients were examined shortly after remission of their last acute psychotic episode and they answered the questionnaires referring to the early phase of this episode. Differences in the questionnaire scores were significant between psychotic patients and controls. Drug induced patients had numerically higher scores than endogenous psychotic patients, however these differences were only significant for the APZ total score and the undifferentiated items of the APZ, but not for the three APZ subscale and the OAV scores. More than 50% of the endogenous psychotic patients answered 26% of the APZ-and 43% of the OAV-items with “yes”. The OAV total score and the OSE (Ozeanische Selbstentgrenzung = oceanic boundlessness) scores of both questionnaires correlated significantly with BPRS Factor 3 (thought disturbance). Our results support the hypothesis that hallucinogen-like experiences represent common phenomena during the acute stages of endogenous psychoses. Remarkably, these phenomena include subjectively pleasant experiences of the OSE dimension. In the routine clinical assessment of endogenous psychotic patients experiences of this dimension may be more easily overlooked than the negative experiences of the AIA dimension (AIA: Angst vor der Ich-Auflösung = dread of ego dissolution).

Type
Original article
Copyright
Copyright © Elsevier, Paris 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association, Third Edition — Revised (DSM III R)Diagnostic and Statistical Manual of Mental Disorders Washington, DC: American Psychiatric Association; 1987.Google Scholar
Beringer, KDer Meskalinrausch Berlin: Springer; 1927.CrossRefGoogle Scholar
Bodmer, I Konstruktion des Fragebogens OAV zut quantitativen Erfassung auβergewöhnlicher Bewuβtseinszustände (ABZ) Thesis 1989 Institute of Psychology, University of ZurichGoogle Scholar
Bonhoeffer, KDie exogenen Reaktionstypen Archiv für Psychiatrie und Nervenkrankheiten 1917; 58: 5870CrossRefGoogle Scholar
Bowers, MBFreedman, DX“Psychedelic” experiences in acute psychosis Arch Gen Psychiatry 1966; 15: 240248CrossRefGoogle Scholar
Chapman, JThe early symptoms of schizophrenia Br J Psychiatry 1960; 112: 225251CrossRefGoogle Scholar
Conrad, KDie symptomatischen PsychosenKisker, KPMeyer, JEMüller, CStrömgen, ECPsychiatrie der Gegenwart Berlin, Heidelberg, New York: Springer; 1972. 170Google Scholar
Dittrich, AÄtiologie-unabhängige Strukturen veränderter Wachbewusstseinszustände Stuttgart: Enke; 1985.Google Scholar
Dittrich, Avon Arx, SStaub, SInternational study on altered states of consciousness (ISASC). Summary of the results German J Psychol 1985; 9: 319339Google Scholar
Fishman, LGDreams, hallucinogenic drug states, and schizophrenia: a psychological and biological comparison Schizophrenia Bull 1983; 9: 7394CrossRefGoogle Scholar
Freedman, BChapman, JEarly subjective experience in schizophrenic episodes J Abnormal Psychol 1973; 82: 4654CrossRefGoogle ScholarPubMed
Gouzoulis, EHermle, LSass, HPsychedelic experiences at the beginning of acute endogenous psychotic episodes Nervenarzt 1994; 65: 198201Google Scholar
Heimann, HAusdrucksphänomenologie der Modellpsychosen (Psilocybin) Psychiat Neurol 1961; 141: 69100CrossRefGoogle Scholar
Hedlund, JLVieweg, BWThe Brief Psychiatric Rating Scale (BPRS): a comprehensive review J Operational Psychiatry 1980; 11: 4864Google Scholar
Hermle, LFünfgeld, MOepen, GBotsch, HBorchardt, DGouzoulis, Eet al.Mescaline-induced psychopathological, neuropsychological neurometabolic effects in normal subjects. Experimental psychosis as a tool for psychiatric research Biol Psychiatry 1992; 32: 97699110.1016/0006-3223(92)90059-9CrossRefGoogle ScholarPubMed
Hermle, LGouzoulis, EOepen, GSpitzer, MKovar, K-ABorchardt, Det al.The significance of hallucinogenic research in psychiatry: history and present status Nervenarzt 1993; 64: 562571Google Scholar
Hollister, LEDrug-induced psychoses and schizophrenic reactions, a critical comparison Ann New York Acad Sci 1962; 96: 8088CrossRefGoogle ScholarPubMed
Krystal, JHKarper, LPSeibyl, JPFreeman, GKDelaney, RBremmer, JDet al.Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans Arch Gen Psychiatry 1994; 51: 199214CrossRefGoogle Scholar
Langeheine, RErwartete Fitwerte für Zufallskonfigurationen in PINDIS Ztschr Sozialpsychol 1980; 11: 3849Google Scholar
Leuner, HCDie experimentelle Psychose. Ihre Psychopharmakologie, Phänomenologie und Dynamik in Beziehung zur Person Berlin: Springer; 1962.Google Scholar
Lingoes, JCBorg, IProcrustean individual difference scaling J Market Res 1976; 13: 406407Google Scholar
Ludwig, AMAltered states of consciousness Arch Gen Psychiatry 1966; 15: 225234CrossRefGoogle ScholarPubMed
McCabe, MSFowler, RCCadoret, RJWinokur, GSymptom differences in schizophrenia with good and poor prognosis Am J Psychiatry 1972; 128: 12391243CrossRefGoogle ScholarPubMed
Overall, JEGorham, DRBrief Psychiatric Rating ScaleW ECDEU, Assessment Manual for Psychopharmacology Rockville: W ECDEU; 1976. 157169Google Scholar
Pechnick, RNUngerleider, JTHallucinogensLowinson, JHRuiz, PMillman, RBLangrod, JGSubstance Abuse A comprehensive textbook 3rd ed 1997 Williams and Wilkins Baltimore230238Google Scholar
Rinkel, MDeshon, HJHyde, RWSolomon, HCExperimental schizophrenia-like symptoms Am J Psychiatry 1952; 108: 572578CrossRefGoogle ScholarPubMed
Rinkel, MHyde, RWSolomon, HCExperimental psychiatry II: Clinical and physiochemical observations in experimental psychosis Am J Psychiatry 1955; 111: 881895CrossRefGoogle Scholar
Schroeter-Rosendahl, C Beginnende Schizophrenie und verändertes Wachbewuβtsein Gesunder: ein empirischer Vergleich mittels einer Selbstbeurteilungsskala Thesis 1980 Medical Faculty, University of ZurichGoogle Scholar
Spitzer, MThimm, MHermle, LHolzman, PSchneider, FGouzoulis, Eet al.Increased activation of indirect semantic associations under Psilocybin Biol Psychiatry 1996; 39: 10551057CrossRefGoogle ScholarPubMed
Stockings, GTA clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenic and other psychotic states J Mental Sci 1940; 86: 2947CrossRefGoogle Scholar
Strassman, RJHallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects J Nerv Ment Dis 1995; 183: 127138CrossRefGoogle ScholarPubMed
Strassman, RJQualls, CRDose-response study of NN-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects Arch Gen Psychiatry 1994; 51: 8597CrossRefGoogle Scholar
Strassman, RJQualls, CRBerg, LMDifferential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans Biol Psychiatry 1996; 39: 784795CrossRefGoogle Scholar
Strassman, RJQualls, CRUhlenhuth, EHKellner, RDoseresponse study of NN-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale Arch Gen Psychiatry 1994; 51: 98108CrossRefGoogle Scholar
Süllwold, LHuber, GSchizophrene Basisstörungen Berlin, Heidelberg, New York: Springer; 1986.CrossRefGoogle Scholar
Vollenweider, FXScharfetter, CLeenders, KLAngst, JDisturbance of serotonergic or glutamatergic neurotransmission results in hyperfrontality as measured by PET and FDG in acute human model psychoses Eur Neuropsychopharmacol 1994 367CrossRefGoogle Scholar
Vollenweider, FXLeenders, KLScharfetter, CAntonin, IAMaguire, PMissimer, Jet al.Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG) Eur Neuropsychopharmacol 1997; 7: 924CrossRefGoogle Scholar
Zarroug, E-TAThe frequency of visual hallucinations in schizophrenic patients in Saudi Arabia Br J Psychiatry 1975; 127: 553555CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.